| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1139: Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more lines of systemic treatment |
|
Medicine details |
|
| Medicine name | epcoritamab (Epkinly®) |
| Formulation | 4 mg/0.8 ml solution for injection |
| Reference number | 5348 |
| Indication | Treatment of relapsed or refractory follicular lymphoma after 2 or more systemic treatments |
| Company | AbbVie Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 11/03/2026 |
| NICE guidance | |